MedTrace Logo

Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsonism

NCT07471230 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-03-13

No results posted yet for this study

Summary

This clinical trial investigates the safety and therapeutic potential of mesenchymal stem cell-based therapies in patients with parkinsonism.

The study evaluates neuroinduced mesenchymal stem cells and mesenchymal stem cell-derived exosomes as potential regenerative treatments targeting neurodegeneration within dopaminergic pathways.

Conditions

  • Parkinsonism or Parkinson's Disease Nos
  • Parkinsonism in Diseases Classified Elsewhere

Interventions

BIOLOGICAL

Intrathecal (IT)

Intrathecal injection of 3 ml between L4-L5

BIOLOGICAL

Intravenous

Intravenous injection via a drip

Sponsors & Collaborators

  • Biocells Medical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
48 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-23
Primary Completion
2028-11-23
Completion
2029-11-23

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07471230 on ClinicalTrials.gov